ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,417.73
-0.08%
Dow Jones
39,838.47
0.08%
Gold vs US Dollar
2,429.89
0.14%
Brent Oil
83.18
-0.42%
Bitcoin
70,166.51
-1.79%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Ask Centralassd (AKCA)

  7. Ask Centralassd (AKCA) News

AKCA Ask Centralassd

0.00
0.00 (0.00%)
Last Updated: -
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ask Centralassd LSE:AKCA London Ordinary Share GB0034031905 ORD 5P(ASSD CITY CENTRE REST SHS & CASH)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Access Pharmaceuticals Common Stock Listed on OTC Bulletin Board

18/05/2006 6:32pm

PR Newswire (US)


Ask Centralassd (LSE:AKCA)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Ask Centralassd Charts.
DALLAS, May 18 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC:AKCA) (BULLETIN BOARD: AKCA) today announced that its common stock is trading on the OTC Bulletin Board under the trading symbol AKCA.OB. Access Pharmaceuticals, Inc. is an emerging pharmaceutical company developing unique polymer linked cytotoxics for use in the treatment of cancer. Its lead product AP5346 is in Phase II clinical testing. The Company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral drug delivery. This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and other reports filed by us with the Securities and Exchange Commission. DATASOURCE: Access Pharmaceuticals, Inc. CONTACT: Stephen B. Thompson, Vice President & CFO of Access Pharmaceuticals, Inc., +1-214-905-5100; or investor relations, Donald C. Weinberger of Wolfe Axelrod Weinberger LLC, +1-212-370-4500, for Access Pharmaceuticals, Inc.

Copyright

1 Year Ask Centralassd Chart

1 Year Ask Centralassd Chart

1 Month Ask Centralassd Chart

1 Month Ask Centralassd Chart

Your Recent History

LSE
AKCA
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved